Attached files
file | filename |
---|---|
EXCEL - IDEA: XBRL DOCUMENT - OMNI BIO PHARMACEUTICAL, INC. | Financial_Report.xls |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
(Mark One)
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Quarterly Period Ended June 30, 2011
or
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 000-52530
Omni Bio Pharmaceutical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Colorado | 20-8097969 | |
(State or other jurisdiction of | (I.R.S. Employer | |
incorporation or organization) | Identification No.) |
5350 South Roslyn, Suite 430, Greenwood Village, CO 80111
(Address of principal executive offices, including zip code)
(Address of principal executive offices, including zip code)
(303) 867-3415
(Registrants telephone number, including area code)
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit and post such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated
filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer o | Accelerated filer þ | Non-accelerated filer o | Smaller reporting company o | |||
(Do not check if a smaller reporting company) |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).
Yes o No þ
The number of shares outstanding of the registrants common stock as of August 8, 2011 was
32,018,396.
TABLE OF CONTENTS
Table of Contents
EXPLANATORY NOTE
Omni Bio Pharmaceutical, Inc. is filing this Amendment No. 1 on Form 10-Q/A (the Form 10-Q/A) to
the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, initially filed
with the Securities and Exchange Commission on August 15, 2011 (the Original Filing),
solely for the purpose of filing the Interactive Data File exhibits required by Item 601(b)(101) of
Regulation S-K. No other part of the Original Filing is being amended, and this Form 10-Q/A has not been updated to reflect
events occurring subsequent to the filing of the Original Filing.
1
Table of Contents
Item 6. | Exhibits. |
EXHIBIT # | DESCRIPTION | |||
3.1 | Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrants
Registration Statement on Form SB-2 filed on March 2, 2007) |
|||
3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrants
Current Report on Form 8-K filed on January 5, 2010) |
|||
3.3 | Articles of Amendment for Across America Financial Services, Inc. including Amendment to
Articles of Incorporation of Across America Financial Services, Inc. (incorporated by
reference to Exhibit 3.3 to the Registrants Current Report on Form 8-K filed on June 2, 2009) |
|||
10.1 | Subscription Agreement and Letter of Investment Intent for the 2011 Private Placement # |
|||
10.2 | Form of Investor Warrant for the 2011 Private Placement # |
|||
10.3 | Form of Placement Agent Warrant for the 2011 Private Placement # |
|||
10.4 | Employment Agreement with James D. Crapo dated July 15, 2011 # |
|||
10.5 | Restricted Stock Unit Agreement with James D. Crapo dated August 10, 2011 # |
|||
10.6 | Restricted Stock Unit Agreement with Charles A. Dinarello dated August 10, 2011 # |
|||
31.1 | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934 # |
|||
31.2 | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) under the Securities
Exchange Act of 1934 # |
|||
32.1 | Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 1350
of Chapter 63 of Title 18 of the United States Code # |
|||
101.INS | XBRL Instance Document** |
|||
101.SCH | XBRL Taxonomy Extension Schema Document** |
|||
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document** |
|||
101.LAB | XBRL Taxonomy Extension Label Linkbase Document** |
|||
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document** |
|||
101 DEF | XBRL Taxonomy Extension Definition Linkbase Document** |
# | Filed with the Original Filing |
|
** | Pursuant to Rule 406T of Regulation S-T, the information in Exhibit 101 is deemed not filed or
part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities
Act of 1933, as amended, is deemed not filed for purposes of Section 18 or the Securities Exchange
Act of 1934, as amended, and otherwise is not subject to liability under these sections. |
2
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
OMNI BIO PHARMACEUTICAL, INC. |
||||
September 14, 2011 | By: | /s/ Robert C. Ogden | ||
Robert C. Ogden | ||||
Chief Financial Officer (Principal Financial and Accounting Officer) |
||||
3